Payment overview · 2025
General Payments
$173,271.46
206 reported records · 28 companies
Healthcare provider profile · identity verified
Michael Howard Gold, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · NASHVILLE, TN · NPI 1073549176
Verified facts
What the public records show
CMS Open Payments records show Michael Howard Gold, M.D. received $173,271.46 in general payments during 2025 across 206 reported records.
ABBVIE INC. accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Opzelura.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opzelura by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OLUMIANT as an associated drug or biological on 560 records involving 277 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Olumiant by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xolair by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90,508.28 | 52.2% | 25 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $31,702.87 | 18.3% | 24 | 2025 |
| Musculoskeletal Transplant Foundation Inc. | Unresolved — no canonical attribution shown | $13,873.58 | 8.0% | 7 | 2025 |
| Botanix SB Inc | Unresolved — no canonical attribution shown | $9,272.33 | 5.3% | 12 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $7,632.09 | 4.4% | 8 | 2025 |
| Lumenis BE inc | Unresolved — no canonical attribution shown | $5,400.00 | 3.1% | 1 | 2025 |
| Lumenis BE (HK) Limited | Unresolved — no canonical attribution shown | $4,772.00 | 2.8% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $3,357.71 | 1.9% | 20 | 2025 |
| STRATA Skin Sciences, Inc. | Unresolved — no canonical attribution shown | $3,063.73 | 1.8% | 9 | 2025 |
| LNHC, Inc | Unresolved — no canonical attribution shown | $1,321.89 | 0.8% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $374.66 | 0.2% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $335.45 | 0.2% | 15 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $265.51 | 0.1% | 10 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $262.03 | 0.1% | 7 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $188.59 | 0.1% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $177.95 | 0.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.87 | 0.1% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $153.46 | 0.1% | 9 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $100.29 | 0.1% | 3 | 2025 |
| Almirall LLC | Unresolved — no canonical attribution shown | $78.68 | 0.1% | 3 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $72.36 | 0.0% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $58.21 | 0.0% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.64 | 0.0% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $30.25 | 0.0% | 1 | 2025 |
| Solta Medical, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.06 | 0.0% | 1 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.55 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.26 | 0.0% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $15.16 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Grant | $85,000.00 | 4 |
| Consulting Fee | $58,432.13 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,650.00 | 7 |
| Honoraria | $6,072.00 | 2 |
| Food and Beverage | $5,107.68 | 176 |
| Education | $9.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $20,200.12 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $15,262.63 | 14 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $9,514.02 | 18 | 2025 |
Source payment records
|
|||||
| SOFDRA Normalized: sofdra |
Drug | Botanix SB Inc | $9,272.33 | 12 | 2025 |
Source payment records
|
|||||
| Leqselvi Normalized: leqselvi |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,123.26 | 2 | 2025 |
Source payment records
|
|||||
| M22 Normalized: m22 |
Device | Lumenis BE inc | $5,400.00 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $3,211.52 | 19 | 2025 |
Source payment records
|
|||||
| XTRAC Normalized: xtrac |
Device | STRATA Skin Sciences, Inc. | $3,063.73 | 9 | 2025 |
Source payment records
|
|||||
| ZELSUVMI Normalized: zelsuvmi |
Drug | LNHC, Inc | $1,321.89 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $527.54 | 17 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $404.91 | 19 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $221.63 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $160.60 | 4 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $153.87 | 3 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $153.46 | 9 | 2025 |
Source payment records
|
|||||
| ILUMYA Normalized: ilumya |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $142.44 | 2 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $134.51 | 7 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $118.44 | 3 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $87.44 | 4 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $84.25 | 2 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $82.87 | 2 | 2025 |
Source payment records
|
|||||
| Seysara Normalized: seysara |
Drug | Almirall LLC | $78.68 | 3 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $72.36 | 2 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $60.14 | 6 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $58.21 | 2 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| CLEAR+BRILLIANT Normalized: clear brilliant |
Not specified | Solta Medical, a division of Bausch Health US, LLC | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Cabtreo Normalized: cabtreo |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| AKLIEF Normalized: aklief |
Drug | Galderma Laboratories, L.P. | $9.99 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $6.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OPZELURA opzelura |
2025 | Opzelura | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | OPZELURA open payments reported associated product |
CMS Open Payments — General Payments 59568 supporting records · 12571 recipient NPIs · example record 1225959946 |
Opzelura · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | OLUMIANT open payments reported associated product |
CMS Open Payments — General Payments 560 supporting records · 277 recipient NPIs · example record 1186464669 |
Olumiant · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Triamcinolone Acetonide | Triamcinolone Acetonide | 260 | 105 |
| Clobetasol Propionate | Clobetasol Propionate | 180 | 79 |
| Fluocinonide | Fluocinonide | 127 | 52 |
| Hydrocortisone | Hydrocortisone | 122 | 58 |
| Ketoconazole | Ketoconazole | 122 | 39 |
| Mupirocin | Mupirocin | 114 | 54 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 35 |
| Ciclopirox | Ciclopirox Olamine | 72 | 30 |
| Dupixent Pen | Dupilumab | 72 | 13 |
| Clindamycin Phosphate | Clindamycin Phosphate | 68 | 18 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 49 | 20 |
| Cephalexin | Cephalexin | 46 | 24 |
| Cosentyx Unoready Pen | Secukinumab | 39 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 14 |
| Humira(Cf) Pen | Adalimumab | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 26 |
| Dupixent Syringe | Dupilumab | 27 | suppressed |
| Desonide | Desonide | 26 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 21 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Humira(Cf) | Adalimumab | 14 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Erivedge | Vismodegib | 11 | suppressed |
| Olumiant | Baricitinib | 11 | suppressed |
| Tazarotene | Tazarotene | 11 | suppressed |
| Xolair | Omalizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173,271.46 · 206 records | ABBVIE INC. | ADBRY, AKLIEF, ANZUPGO, BOTOX, Bimzelx, CIBINQO, CLEAR+BRILLIANT, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, HADLIMA, ILUMYA, INNOVAMATRIX AC, JUBLIA, LITFULO, Leqselvi, M22, NEMLUVIO, NUZYRA, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SKYRIZI, SOFDRA, Seysara, TALTZ, TREMFYA, VTAMA, Winlevi, XTRAC, ZELSUVMI, Zoryve | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Opzelura play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Incyte Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error